Avance Biosciences is proud to participate in Advanced Therapies USA 2025, showcasing our CGMP and GLP-compliant testing services to support the development of next-generation cell and gene therapies.[...]
Avance Biosciences is excited to exhibit at AAPS 2025 PharmSci 360! Discover our CGMP- and GLP-compliant bioanalytical and analytical services supporting next-generation therapies, from RNA and gene/cell therapies to ADCs and exosome-based modalities[...]
Avance Biosciences is proud to participate in the 2025 World ADC Conference, highlighting our CGMP- and GLP-compliant analytical expertise supporting the development of antibody-drug conjugates. From assay development and validation to comprehensive bioanalytical testing, our services empower biopharmaceutical innovators to advance safer, more effective targeted therapies.[...]
Avance delivers end-to-end NGS workflow compliance with a robust framework for data integrity, pipeline validation, and audit readiness—tailored for regulated environments...
Avance Biosciences™ will exhibit at BPI International 2025 in Boston, showcasing our end-to-end analytical and testing services for biologics, cell, and gene therapies. Visit booth 1508 to learn about our NGS Center of Excellence, offering advanced sequencing, on/off-target detection, and gene editing safety assessments...
Avance Biosciences’ NGS Center of Excellence delivers comprehensive sequencing solutions, including short-read, long-read, and advanced single-cell platforms. Our regulatory-compliant workflows support biologics, gene, and cell therapy programs with high-quality data, enabling informed development...
Avance Biosciences™ will not only be exhibiting (booth #516), but also presenting two posters as part of the Next-Generation Analytical Methods program: Genome-wide Mapping of CRISPR-Cas Off-Target Cleavage Sites via GUIDE-Seq & Digitally Secure Sequencing: Implementing Part 11-Ready NGS Data Security in a CRO Environment...
To support IND-enabling studies, a biotech company needed precise measurement of in vivo gene-editing efficiency in preclinical rat tissues. Avance Biosciences delivered a fully validated NGS amplicon sequencing assay capable of detecting edits as low as 1%, enabling accurate quantification across multiple tissues and guiding data-driven development decisions.
When a gene therapy company needed to verify plasmid identity, purity, and integrity for an IND submission, Avance Biosciences delivered a validated NGS-based solution. The assay enabled low-level variant detection and trace contaminant analysis, supporting FDA compliance and lot release.
Avance Biosciences is proud to announce the partial commissioning of our new GMP facility at 5500 Northwest Central Drive in Houston, Texas. Effective July 21, 2025, select Biologics Quality Control services, including Microbiology and Sanger sequencing, will transition from our West Little York site to this new location. Please begin shipping samples directly to the new facility as we continue to expand our capabilities to better serve our clients.
Avance Biosciences is a leading Contract Research Organization (CRO) and Contract Testing Organization (CTO) providing CGMP and GLP-compliant analytical and bioanalytical services to support drug development. From early discovery through clinical development and commercialization, we provide CGMP and GLP-compliant services tailored to your therapeutic modality and regulatory needs.
